1. Title Author(s), Institution Introduction Methods Results Discussion Conclusions References Reporting of the emergence of echinocandin resistant Candida glabrata is increasing worldwide, with antifungal usage often being the major factor. Our facility’s incidence of C. glabrata rose from 21% of all Candida sp. bloodstream infections in 2009 to 37% by 2011. Due to this increase, we assessed our usage of antifungals and its impact on the acquisition of the fks1 hotspot (HS) mutation in C. glabrata. echinocandin resistant Candida glabrata is increasing worldwide, with antifungal usage often being the major factor. Our facility’s incidence of C. glabrata rose from 21% of all Candida sp. Reporting of the emergence of echinocandin resistant Candida glabrata is increasing worldwide, with antifungal usage often being the major factor. Our facility’s incidence of C. glabrata rose from 21% of all Candida sp. bloodstream infections in 2009 to 37% echinocandin resistant Candida glabrata is increasing worldwide, with antifungal usage often being the major factor. Our facility’s inci, with antifungal usage often being the major factor. Our facility’s dence of C. glabrata rose from 21% of all Candida sp. bloodstream infections in 2009 to 37% by 2011. Due to this increase, we assessed our usage of antifungals and its impact on the usage of antifungals and its impact on the acquisition of the fks1 hotspot (HS) mutation in C. glabrata. Due to this increase, we assessed our usage of antifungals and its impact on the acquisition of the fks1 hotspot (HS) mutation in C. glabrata. Reporting of the emergence of echinocandin resistant Candida glabrata is increasing worldwide, with antifungal usage often being the major factor. Our facility’s incidence of C. glabrata rose from 21% of all Cechinocandin resistant Candida glabrata is increasing worldwide, with antifungal usage often being the major factor. Our facility’s, with antifungal usage often being the major factor. Our facility’s incidence of C. glabrata rose from 21% of all Candida sp. bloodstream infections in 2009 to 37% by 2011. Due to this increase, we assessed our usage of antifungals and its impact on th. Reporting of the emergence of echinocandin resistant Candida glabrata is increasing worldechinocandin resistant Candida glabrata is increasing worldwide, with antifungal usage often being the major factor. Our facility’s incidence of C. glabrata rose from 21% of all Candida sp. bloodstream infections in 2009 to 37% by 2011. Due to this increase, we assessed our usage of antifungals and its impact on the wide, with antifungal usage often being the major factor. Our facility’s incidence of C. glabrata rose from 21% of all Candida sp. bloodstream Reporting of the emergence of echinocandin resistant Candida glabrata is increasing worldwide, with antifungal usage often being the major factor. Our facility’s incidence of C. glabrata rose from 21% of all Candida sp. bloodstreamReporting of the emergence of echinocandin resistant Candida glabrata is increasing worldwide, with antifungal usage often being the major factor. Our facility’s incidence of C. glabrata rose from 21% of aechinocandin resistant Candida glabrata is increasing worldwide, with antifungal usage often being the major factor. Our facility’s incidence of C. glabrata rose from 21% of all Candida sp. bloodstream infections in 2009 to 37% by 2011. Due to this increase, we assessed our usage of antifungals and its impact on the echinocandin resistant Candida glabrata is increasing worldwide, with antifungal usage often being the major factor. Our facility’s incidence of C. glabrata rose from 21% of all Candida sp. bloodstream, with antifungal usage often being the major factor. Our facility’s infections in 2009 to 37% by 2011. Due to this increase, we assessed our usage of antifungals and its impact on the ll Candida sp. bloodstream Reporting of the emergence of echinocandin resistant Candida glabrata is increasing worldwide, with antifungal usage often being the major factor. Our facility’s incidence of C. glabrata rose from 21% of all Candida sp. Bloodstream